Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) news covers the company’s progress as a biopharmaceutical issuer focused on therapies for autoimmune diseases with high unmet medical needs. Investors and followers of AUPH can use this page to review company‑issued updates, financial announcements and clinical data disclosures that shape the outlook for its products and pipeline.
News releases from Aurinia frequently highlight commercial performance and medical data for LUPKYNIS (voclosporin), which the company describes as the first FDA‑approved oral therapy for adult patients with active lupus nephritis. Regular quarterly earnings announcements detail trends in net product sales of LUPKYNIS, license, collaboration and royalty revenue, net income and cash flows. These updates are often accompanied by guidance ranges for total revenue and net product sales, as well as information on the company’s share repurchase plan.
In addition to financial results, Aurinia’s news flow includes clinical and scientific milestones. The company has reported post‑hoc analyses from the AURORA 1 trial, real‑world data from the ENLIGHT‑LN registry and new mechanistic findings on voclosporin, often presented at major rheumatology and nephrology meetings. Separate announcements describe progress with aritinercept (AUR200), a dual BAFF and APRIL inhibitor, including Phase 1 study results and plans for further clinical development in autoimmune diseases.
Visitors to this AUPH news page can review a stream of earnings releases, pipeline updates, medical conference presentations and regulatory‑related communications drawn from company press releases and SEC‑referenced materials. This provides a centralized view of how Aurinia communicates its commercial performance, clinical findings and strategic steps in autoimmune disease drug development.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS to be below the $150,000 willingness-to-pay threshold, costing $88,076 per QALY and $77,643 per evLYG for adults with active LN. For Black, Hispanic, and Latino patients, costs were $77,436 per QALY and $67,828 per evLYG. Additional data from the AURORA clinical program and the Enlight-LN registry highlighted the drug's sustained efficacy and reduced steroid use over three years. A propensity analysis indicated superior proteinuria reduction and decreased exposure to toxicities versus high-dose glucocorticoid regimens.
Aurinia Pharmaceuticals Inc. presented data at the Congress of Clinical Rheumatology East 2024, reinforcing the safety and efficacy of LUPKYNIS in treating lupus nephritis. The studies showed that LUPKYNIS in combination with standard care reduced toxicities and proteinuria compared to conventional treatments. Black patients experienced improved outcomes with LUPKYNIS.
A shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has urged the Board of Directors to take action to enhance shareholder value. The shareholder, Lucien Selce, expressed concerns about the Company's current strategy, Board composition, and market penetration. He outlined the need for restructuring the Board, setting clear objectives for market penetration, and developing strategic partnerships to improve performance and shareholder value.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Management will host one-on-one meetings with investors and participate in a fireside chat. A live webcast of the session will be available on the company's website.
Aurinia Pharmaceuticals Inc. reported $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, with a year-over-year growth of approximately 46% and 40% respectively. The company achieved significant milestones like FDA approval for LUPKYNIS and plans to reach positive free cash flows in Q2 2024. The 2024 net product revenue guidance is $200 to $220 million. Financially, total net revenue increased, operating expenses decreased, and the company maintained a strong liquidity position.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reaffirms its commitment to raising awareness about lupus nephritis (LN) during Lupus Awareness Month. The company is engaging in various education initiatives to improve understanding, screening, and management of LN. Through partnerships and advocacy efforts, Aurinia aims to eliminate barriers to access, promote equity, and enhance health outcomes for individuals affected by LN.
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required after the first year of treatment. The safety profile of LUPKYNIS remains unchanged and aligns with the AURORA clinical program's findings.
Summary not available.
Summary not available.
Summary not available.